| The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment‐naïve hepatitis C patients R Flisiak, SV Feinman, M Jablkowski, A Horban, W Kryczka, ... Hepatology 49 (5), 1460-1468, 2009 | 281 | 2009 |
| Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B ER Schiff, SS Lee, YC Chao, SK Yoon, F Bessone, SS Wu, W Kryczka, ... Clinical Gastroenterology and Hepatology 9 (3), 274-276. e1, 2011 | 245 | 2011 |
| Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in hepatitis C: AMBER study R Flisiak, E Janczewska, M Wawrzynowicz‐Syczewska, J Jaroszewicz, ... Alimentary pharmacology & therapeutics 44 (9), 946-956, 2016 | 141 | 2016 |
| Albinterferon alfa‐2b dosed every two or four weeks in interferon‐naïve patients with genotype 1 chronic hepatitis C S Zeuzem, EM Yoshida, Y Benhamou, S Pianko, VG Bain, D Shouval, ... Hepatology 48 (2), 407-417, 2008 | 103 | 2008 |
| Chemerin, vaspin and insulin resistance in chronic hepatitis C M Kukla, K Zwirska‐Korczala, A Gabriel, M Waluga, I Warakomska, ... Journal of viral hepatitis 17 (9), 661-667, 2010 | 89 | 2010 |
| Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3 DR Nelson, Y Benhamou, WL Chuang, EJ Lawitz, M Rodriguez–Torres, ... Gastroenterology 139 (4), 1267-1276. e4, 2010 | 83 | 2010 |
| 4 ONCE DAILY ALISPORIVIR (DEB025) PLUS PEGIFNALFA2A/RIBAVIRIN RESULTS IN SUPERIOR SUSTAINED VIROLOGIC RESPONSE (SVR24) IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT NAIVE PATIENTS R Flisiak, JM Pawlotsky, R Crabbe, PI Calistru, W Kryczka, D Haüssinger, ... Journal of hepatology, S2, 2011 | 69 | 2011 |
| Distribution of HCV genotypes in Poland OCWUM w Łodzi, OC Zakaźnych, SS w Chorzowie, WPCI i Hepatologii, ... Przegl Epidemiol 66, 11-16, 2012 | 49 | 2012 |
| Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment‐naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II) S Zeuzem, R Flisiak, JM Vierling, W Mazur, G Mazzella, S Thongsawat, ... Alimentary Pharmacology & Therapeutics 42 (7), 829-844, 2015 | 47 | 2015 |
| Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C. W Kryczka, E Brojer, A Kowalska, D Zarebska-Michaluk Medical science monitor: international medical journal of experimental and …, 2001 | 41 | 2001 |
| Visfatin serum levels in chronic hepatitis C patients M Kukla, K Żwirska‐Korczala, A Gabriel, M Waluga, I Warakomska, ... Journal of viral hepatitis 17 (4), 254-260, 2010 | 39 | 2010 |
| Extrahepatic manifestations associated with chronic hepatitis C infections in Poland DA Zarebska-Michaluk, DM Lebensztejn, WM Kryczka, E Skiba Advances in Medical Sciences 55 (1), 67-73, 2010 | 37 | 2010 |
| Prevalence of HCV genotypes in Poland–the EpiTer study R Flisiak, J Pogorzelska, H Berak, A Horban, I Orłowska, K Simon, ... Clinical and experimental hepatology 2 (4), 144-148, 2016 | 32 | 2016 |
| Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated Interferon alpha-2a in treatment naïve mono-infected HCV patients … R Flisiak, SV Feinman, M Jablkowski, A Horban, W Kryczka, W Halota, ... Journal of Hepatology 48, S62-S62, 2008 | 31 | 2008 |
| DRB1 alleles in relation to severity of liver disease in patients with chronic hepatitis C. W Kryczka, E Brojer, A Kalińska, A Urbaniak, D Zarebska-Michaluk Medical Science Monitor: International Medical Journal of Experimental and …, 2001 | 31 | 2001 |
| Acute seronegative hepatitis C manifesting itself as adult giant cell hepatitis--a case report and review of literature. W Kryczka, B Walewska-Zielecka, E Dutkiewicz Medical Science Monitor: International Medical Journal of Experimental and …, 2003 | 26* | 2003 |
| The hepatitis C virus genotype and subtype frequency in hepatitis C virus RNA‐positive, hepatitis C virus antibody‐negative blood donors identified in the nucleic acid test … E Brojer, A Gronowska, J Medyńska, P Grabarczyk, M Mikulska, ... Transfusion 44 (12), 1706-1710, 2004 | 25 | 2004 |
| Efficacy of HCV treatment in Poland at the turn of the interferon era–the EpiTer study R Flisiak, J Pogorzelska, H Berak, A Horban, I Orłowska, K Simon, ... Clinical and Experimental Hepatology 2 (4), 138-143, 2016 | 23 | 2016 |
| Effect of peginterferon or ribavirin dosing on efficacy of therapy with telaprevir in treatment-experienced patients with chronic hepatitis C and advanced liver fibrosis: a … E Janczewska, R Flisiak, D Zarebska-Michaluk, D Kozielewicz, H Berak, ... Medicine 94 (38), e1411, 2015 | 19 | 2015 |
| Analysis of hepatitis G virus infection markers in blood donors and patients with hepatitis E Brojer, P Grabarczyk, W Kryczka, W Kucharski, J Kubicka, B Z· upánska Journal of Viral Hepatitis 6 (6), 471-475, 1999 | 17 | 1999 |
